the letter highlights concerns about the lack of disclosure of conflicts of interest in correspondence published in nature biotechnology. in august 2003, over 30 scientists and the center for science in the public interest (cspi) urged nature journals to strengthen policies for disclosing potential conflicts of interest among authors and quoted experts. the letter points to a case where the nature journal failed to disclose corporate affiliations of authors in a correspondence, contradicting the journal's aim of transparency. david schubert, who had financial ties to biotech companies, wrote a commentary on the safety of genetically modified (gm) foods. in response, 18 scientists disputed schubert's arguments, but many of these authors had close ties to companies that benefit from agricultural biotechnology. the letter argues that financial interests should be disclosed in scientific debates, especially on controversial topics like gm foods. while industry funding does not necessarily undermine research quality, there is evidence of a correlation between industry funding and opinions favoring industry interests. the letter urges nature journals to extend their disclosure policy to include correspondence. the editor's note states that nature biotechnology and other nature journals are reviewing whether to expand their competing interests policy to include correspondence. the letter also addresses the 'lilly doctrine,' which is relevant to patent law and the protection of biotechnology in pharmaceutical applications. the letter argues that the 'lilly doctrine' is viable and critical for protecting biotechnology.the letter highlights concerns about the lack of disclosure of conflicts of interest in correspondence published in nature biotechnology. in august 2003, over 30 scientists and the center for science in the public interest (cspi) urged nature journals to strengthen policies for disclosing potential conflicts of interest among authors and quoted experts. the letter points to a case where the nature journal failed to disclose corporate affiliations of authors in a correspondence, contradicting the journal's aim of transparency. david schubert, who had financial ties to biotech companies, wrote a commentary on the safety of genetically modified (gm) foods. in response, 18 scientists disputed schubert's arguments, but many of these authors had close ties to companies that benefit from agricultural biotechnology. the letter argues that financial interests should be disclosed in scientific debates, especially on controversial topics like gm foods. while industry funding does not necessarily undermine research quality, there is evidence of a correlation between industry funding and opinions favoring industry interests. the letter urges nature journals to extend their disclosure policy to include correspondence. the editor's note states that nature biotechnology and other nature journals are reviewing whether to expand their competing interests policy to include correspondence. the letter also addresses the 'lilly doctrine,' which is relevant to patent law and the protection of biotechnology in pharmaceutical applications. the letter argues that the 'lilly doctrine' is viable and critical for protecting biotechnology.